Mylicon (Simethicone) is used across several therapeutic domains to provide symptomatic relief focused exclusively on gas-related discomfort and its physical manifestations. The medication is commonly used to treat symptoms of gas such as pressure and bloating.

The medication is commonly used to provide supportive relief for symptoms related to functional gastric bloating, uncomfortable fullness, and painful pressure caused by trapped air. This therapeutic support is generally relevant when symptoms interfere with daily comfort. The medication is commonly used to help manage episodes of excess gas, infant gas distress, and specific clinical scenarios like postoperative gas pains.

“The medication helps manage the distressing physical sensations that arise when trapped air creates tension in the abdomen.”

Applied during acute phases, Mylicon contributes to improved day-to-day comfort by helping to ease the physical distress. In the pediatric population, this usage supports general well-being during symptomatic phases.

Quick Fact: Symptomatic Relief
Provides support for bloating, pressure, and fullness in the abdomen.
Used for infant gas distress and postoperative gas pains.

Regulatory References

1. NIH MedlinePlus Drug Information

Eligibility for Mylicon (Simethicone) Use

The eligibility for Mylicon is defined primarily by its non-systemic nature, meaning the drug is not absorbed into the bloodstream. This property allows for broad use across nearly all populations, as established by regulatory authorities.

---

Category	Regulatory Status	Status Detail
Populations Contraindicated	Absolute Prohibition	Patients with a known hypersensitivity or allergy to simethicone or any other ingredient in the product formulation [Source 1.4, 4.2].
Age-Group Eligibility	Permitted for All Ages	Use is authorized for Infants (including newborns), children, adolescents, and older adults. No specific geriatric restrictions are cited [Source 1.1, 4.5].
Pregnancy and Lactation	Permitted for Use	Use is permitted during pregnancy and breastfeeding because the drug is not absorbed orally and is not expected to be excreted into breast milk [Source 2.1, 2.2].
Condition-Based Restrictions	Conditional Use/Caution	Individuals with Phenylketonuria (PKU) must check the specific product label, as some forms may contain phenylalanine [Source 1.3]. Users must consult a health professional if symptoms persist for more than 14 days [Source 4.3].
Organ-Function Limits	Not Applicable (N/A)	No official restriction or dosage adjustment is required for patients with renal or hepatic impairment [Source 4.2, 4.5].

---

Connection to the overall eligibility profile

The regulatory profile broadly permits Simethicone use across all major patient groups due to its lack of systemic absorption. The only absolute prohibition is for documented allergies to the drug, with all other use limitations restricted to caution for persistent symptoms or specific inactive ingredients.

Simethicone, the active ingredient in Mylicon, is classified by regulatory authorities as a non-systemic antiflatulent agent. The substance is not absorbed into the bloodstream, a fundamental property that severely limits the potential for complex systemic drug interactions. Due to this non-systemic profile, government regulatory documents list no formally contraindicated combinations, no CYP enzyme-mediated metabolic interactions, and no systemic pharmacodynamic effects with other medicines.

The official interaction profile is defined by a single documented local physical mechanism: absorption interference within the gastrointestinal tract.

Documented Interaction and Restriction

Category	Description from Regulatory Labels
Interacting Medicine	Levothyroxine (thyroid hormone replacement).
Interaction Outcome	Co-administration may reduce the gastrointestinal absorption of Levothyroxine, potentially leading to reduced systemic exposure.
Timing Restriction	A mandatory administration separation of at least 4 hours is required between Simethicone and Levothyroxine.

This interaction is classified as clinically significant, requiring a modification of the administration schedule to mitigate the risk of reduced therapeutic exposure. Furthermore, official regulatory documents do not contain specific warnings or restrictions regarding interactions between Simethicone and food, alcohol, or herbal products.

The Physicochemical Mechanism of Simethicone

The active ingredient, Simethicone, functions through a purely physicochemical mechanism, which is non-systemic; its action is exerted entirely within the gastrointestinal (GI) tract without being absorbed or interacting with classical biological targets like receptors or enzymes. Simethicone operates as an antifoaming agent by acting directly at the gas-liquid interface inside the gut.

Surfactant Action and Gas Mobilization

Simethicone acts as a surfactant by drastically lowering the surface tension of the fluid surrounding the numerous tiny air pockets trapped in the GI tract's contents. This action destabilizes the walls of the foamy bubbles .

This destabilization initiates a mechanistic cascade known as coalescence, causing the multitude of small, stable bubbles to merge into fewer, much larger, gas masses. This alteration of the gas's geometry transforms trapped foam into free gas that is cleared via the body’s natural mechanisms of eructation or flatulence. This physical clearance involves the removal of large gas masses and shapes the drug's predictable physiological effect profile.

The administration of Simethicone, the active ingredient in Mylicon, is strictly by the oral route across all approved dosage forms, which include liquid drops, chewable tablets, and capsules. The protocol structures the use of the medicine as an intermittent, as-needed (PRN) pattern for symptom occurrence, rather than a continuous, scheduled regimen. Doses are typically to be taken after meals and at bedtime to align the medication's action with periods of high gas production.

For self-medication in adults and children 12 years and older, the standard dosage ranges from 40 mg to 125 mg per dose, with the maximum daily intake for all forms not to exceed 500 mg in any 24-hour period. Administration for the pediatric population is strictly stratified by age with specific maximums. Infants under 2 years are dosed at 20 mg (0.3 mL), and children aged 2 to 12 years are dosed at 40 mg (0.6 mL), with corresponding lower daily maximum limits.

Proper use requires specific preparatory steps. Liquid suspensions must be shaken well prior to measuring to ensure content uniformity, and the dose should be measured using the dedicated device. The liquid dose may be mixed with 1 ounce of cool water, infant formula, or other suitable liquids. Chewable tablets, conversely, must be thoroughly chewed prior to swallowing to ensure the correct physical dispersion of the active ingredient. The maximum daily quantity established for any age group must not be surpassed.

Research Evidence / Overview of Studies for Mylicon

---

Research Evidence for General Gas Discomfort

Research has examined the use of Simethicone, the active ingredient in Mylicon, in trials assessing short-term or episodic symptom patterns related to trapped gas. These studies, which include Randomized Controlled Trials (RCTs) and various reviews, focused mainly on adults who were experiencing outcomes related to physical discomfort such as bloating, feelings of fullness, and abdominal pressure. Simethicone was studied for how the outcomes related to physical discomfort evolved in these symptoms, often in comparison to a placebo (an inactive substance).

In these studies, findings describe patterns observed related to the patient-reported outcomes describing perceived discomfort. Research highlights changes measured during the study period using patient-reported outcomes describing perceived discomfort. However, the data show patterns related to symptom management over typically short timeframes, and findings were mixed when Simethicone was evaluated in specific patient groups with complex digestive issues, such as those with functional dyspepsia or Irritable Bowel Syndrome (IBS).

---

Studies on Infant Gas Distress and Colic

The evidence base for using Simethicone drops for infant gas and colic has been explored through placebo-controlled trials. These trials monitored outcomes capturing phases of heightened symptom activity, specifically measuring carer-reported total crying time per day in infants, typically newborns up to 12 weeks old, diagnosed with colic. When these studies report how symptoms evolved in the observed populations, the findings were mixed. Systematic reviews have described that the observed changes measured during the study period in daily crying time were often not significantly different from those reported by caregivers of infants who received a placebo, meaning certainty remains low when relying on the most rigorous controlled studies concerning the standard definition of infant colic.

---

Research as an Aid in Diagnostic Procedures

Simethicone was studied for a distinct, non-symptomatic purpose: its physical application as an antifoaming agent during gastrointestinal procedures. Meta-analyses consistently report that the use of Simethicone was associated with an observed and measured decrease in residual foam, which was observed to correspond with improved quality of visualization for the medical team during procedures like colonoscopy. However, the subgroup findings are uncertain regarding the optimal way to use the medicine during preparation.

---

Key Limitations and Unanswered Research Questions

The body of research has identified several areas where data are still emerging: most therapeutic studies have limited information for long-term outcomes due to follow-up durations being limited. Additionally, many findings depend on patient-reported outcomes describing perceived discomfort (e.g., pain scales), which can make interpreting the consistency of results challenging.

Key Studies & References

1. MedlinePlus Drug Information: Simethicone (Oral Route)

Common questions about Mylicon (FAQ)

---

Q: Is Mylicon considered a treatment for colic, or is it only for gas symptoms?

Regulatory documents classify the active ingredient, Simethicone, as an antiflatulent agent intended for the relief of general gas symptoms. While research has examined its use for infant colic, systematic reviews report that evidence for a significant effect on the total crying time for infants with colic is often mixed.

---

Q: Is there a recommended waiting period between doses for the effect to build up?

According to official administration instructions, the medication is intended for intermittent, as-needed (PRN) use for symptom occurrence. The product label specifies timing relative to meals and bedtime, but does not provide a general, required waiting period between individual doses for the effect to accumulate.

---

Q: If Mylicon is given before a feeding, will it still be effective against gas that forms later?

Official administration instructions recommend taking the dose after meals and at bedtime. This timing is typically recommended because it aligns with periods when gas production is often expected to be highest.

---

Q: Is it safe to give Mylicon daily for an extended period, such as several months?

The official labeling specifies a maximum daily quantity that should not be surpassed for any age group. The label also notes that users should consult a health professional if symptoms persist for more than 14 days of continuous use.

---

Q: Is there a risk of a baby developing a dependency or tolerance to Mylicon over time?

Regulatory documents describe the active ingredient, Simethicone, as acting through a purely physicochemical, non-systemic mechanism. Because it is not absorbed into the body and does not interact with biological receptors, this mechanism of action indicates that it is not associated with the development of dependency or tolerance.

---

Q: Is there an age or weight limit where an infant should stop using Mylicon?

The specific infant formulation and dosing are primarily authorized for use in infants up to the age of 2 years. After this age, administration requirements change to the children's dosage.

---

Q: Can a person be allergic to the active ingredient, simethicone?

Yes, official documents state that Simethicone is formally contraindicated in individuals with known hypersensitivity or allergy to the active substance or any of its components.

---

Q: What are the recommended storage requirements for Mylicon drops (temperature, light)?

Regulatory requirements specify storing the product at controlled room temperature, which is between 20-25 C (68-77 F). The medication must also be protected from freezing.

---

Q: Can Mylicon interact with thyroid hormone medications, such as levothyroxine?

Co-administration of Simethicone with Levothyroxine may reduce the gastrointestinal absorption of Levothyroxine. Official regulatory documents state that an administration separation of at least 4 hours is necessary between the two medicines to mitigate the risk of reduced therapeutic exposure.

---

Q: Can Mylicon be given at the same time as probiotic drops?

Official regulatory documents list no formally contraindicated systemic combinations with other medicines, due to the drug's non-systemic profile. There is no specific regulatory guidance regarding the co-administration with probiotics.

---

Q: Is there specific clinical evidence about Mylicon's use for general infant fussiness, separate from gas relief?

Research has examined Simethicone’s use in infants with outcomes primarily focused on crying time and relief of gas discomfort. Official documents do not define or address the separate condition of 'general fussiness' as a specific indication.

---

Q: Is Mylicon only for babies, or can older children and adults use it too?

Use is authorized across a broad range of ages, including Infants (under 2 years), children (2 to 12 years), and adults (12 years and older). Specific dosage and dose form requirements exist for each age group.

---

Q: Does Mylicon treat abdominal pain from gas in general?

Simethicone is approved for the relief of physical discomfort, which includes pressure, bloating, and feelings of fullness. The official regulatory labeling does not explicitly list the more general term 'abdominal pain' as an indication.

---

Q: Why do some people say the effect seems immediate?

The active ingredient works via a physicochemical mechanism on the surface tension of gas bubbles. This action is an immediate, localized physical process that begins as soon as the active ingredient reaches the site of trapped gas.

---

Q: Does Mylicon have an expiration date that affects its safety or effectiveness?

Yes, regulatory requirements mandate that all drug products include an expiration date based on stability testing. The drug should not be used if this date has passed.

---

Q: What inactive ingredients are in the Mylicon drops?

The FDA label is required to list the full complement of inactive ingredients in the drug product. The specific inactive ingredients define the complete formulation of the drops.

---

Q: Is there a difference in ingredients between the brand name Mylicon and generic simethicone?

Generic products are required to contain the same active ingredient (Simethicone) in the same concentration as the brand name. However, official guidelines allow for inactive ingredients to vary between brand name and generic versions.

---

Q: Does Mylicon contain sodium bicarbonate, like some other tummy relief products?

The FDA label is required to list all active and inactive ingredients in the product. Consulting this list will confirm the presence or absence of sodium bicarbonate in the specific formulation.

---

Q: Is the flavor added to Mylicon drops safe for newborns?

The entire formulation, including all inactive components such as the flavor, is subject to regulatory review and approval for use in the infant and newborn population.

The official regulatory requirements for storing and disposing of Mylicon oral liquid emphasize temperature control, protection from freezing, and secure handling.

Storage Requirements

• Temperature: Store at controlled room temperature, which is between 20-25 C (68-77 F).
• Handling: The medication must be protected from freezing.
• Security: As with all medicines, it must be kept out of the reach of children.
• Integrity: Do not use the product if the tamper-evident seal is broken or missing.

Disposal Instructions

To dispose of unused or expired medicine, follow standard FDA non-flush guidelines. This involves mixing the medication with an unappealing substance, such as dirt or used coffee grounds, placing the mixture into a sealed bag or container, and discarding it in the household trash.